Announced Thu, 25 Jun · 18:13 IST
Jagsonpal Pharma appoints Anil Matai as Independent Director for 5 years
Management Changes View source PDF
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.6%1-day move
₹223.00
prior close
₹222.32
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+2.4+2.7—+7.6+6.5+5.3+6.6+6.7+2.6+0.0———
Up moveDown movePending
AI summary
Jagsonpal Pharmaceuticals has appointed Mr. Anil Kumar Matai (DIN 03122685) as an Additional Non-Executive Independent Director effective June 25, 2026, for a term of 5 years subject to shareholder approval. Matai brings over 35 years of life sciences experience and currently serves as Director General of OPPI. His prior roles include CEO of Novartis India, President and MD of Zydus Healthcare, and Operating Partner at Jashvik Capital.
Likely market impact
Adds a seasoned pharma industry veteran to the board. Routine governance move, subject to shareholder approval. Likely neutral for the stock.